Evercore ISI Group Lowers Price Target for Exact Sciences (EXAS) to $64
ByAinvest
Sunday, Aug 10, 2025 7:40 pm ET1min read
EVR--
Exact Sciences reported total revenue of $811.09 million for Q2 2025, a 16.0% increase from the same period in 2024. The Screening segment drove much of this growth, contributing $628.48 million, a 18.0% increase, while the Precision Oncology segment also showed robust performance with revenue of $182.60 million, up 9.0% year-over-year [1]. Despite the positive revenue growth, the company narrowed its net loss by 92.5% to $1.19 million, or $0.01 per share, compared to a net loss of $-15.81 million, or $0.09 per share, in Q2 2024. This represents an 88.9% improvement in EPS and a 92.5% reduction in net loss [1].
The new price target of $64.00 reflects the company's improved financial performance and operational efficiency. The price target represents approximately 2 times average calendar year 2025/2026 enterprise value to revenue, 3 times enterprise value to gross profit, and a 4.4% free cash flow yield, according to Evercore ISI [1].
However, the stock has experienced volatility in recent weeks, with a 10.67% jump on the latest trading day followed by an 8.07% drop during the subsequent full trading week. Over the month-to-date, the stock has fallen 19.39% [1]. This volatility reflects investor sentiment and market reactions to the earnings report and broader market conditions.
Despite the recent price action, Evercore ISI remains optimistic about Exact Sciences' long-term prospects. The company's strategic initiatives, such as the acquisition of Freenome's blood-based colorectal cancer screening tests and the launch of a multi-year productivity plan targeting $150 million in annual savings by 2026, indicate a focus on expanding its diagnostic offerings and improving operational efficiency [1].
References:
[1] https://www.ainvest.com/news/exact-sciences-evercore-isi-group-maintains-outperform-pt-64-2508/
EXAS--
Evercore ISI Group has maintained an "Outperform" rating for Exact Sciences (EXAS) but lowered the price target from $68 to $64. This reflects the latest insights and adjustments by the analyst to the company's projected performance. The average target price for EXAS is $64.42 with a high estimate of $80 and a low estimate of $46. The average brokerage recommendation is 1.7, indicating "Outperform" status.
Evercore ISI Group has maintained its "Outperform" rating for Exact Sciences (EXAS) but has lowered its price target from $68 to $64, reflecting the latest insights and adjustments to the company's projected performance. This move comes despite the company's strong Q2 2025 earnings, which showed significant reductions in net losses and increases in revenue guidance [1].Exact Sciences reported total revenue of $811.09 million for Q2 2025, a 16.0% increase from the same period in 2024. The Screening segment drove much of this growth, contributing $628.48 million, a 18.0% increase, while the Precision Oncology segment also showed robust performance with revenue of $182.60 million, up 9.0% year-over-year [1]. Despite the positive revenue growth, the company narrowed its net loss by 92.5% to $1.19 million, or $0.01 per share, compared to a net loss of $-15.81 million, or $0.09 per share, in Q2 2024. This represents an 88.9% improvement in EPS and a 92.5% reduction in net loss [1].
The new price target of $64.00 reflects the company's improved financial performance and operational efficiency. The price target represents approximately 2 times average calendar year 2025/2026 enterprise value to revenue, 3 times enterprise value to gross profit, and a 4.4% free cash flow yield, according to Evercore ISI [1].
However, the stock has experienced volatility in recent weeks, with a 10.67% jump on the latest trading day followed by an 8.07% drop during the subsequent full trading week. Over the month-to-date, the stock has fallen 19.39% [1]. This volatility reflects investor sentiment and market reactions to the earnings report and broader market conditions.
Despite the recent price action, Evercore ISI remains optimistic about Exact Sciences' long-term prospects. The company's strategic initiatives, such as the acquisition of Freenome's blood-based colorectal cancer screening tests and the launch of a multi-year productivity plan targeting $150 million in annual savings by 2026, indicate a focus on expanding its diagnostic offerings and improving operational efficiency [1].
References:
[1] https://www.ainvest.com/news/exact-sciences-evercore-isi-group-maintains-outperform-pt-64-2508/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet